Research Article

Assessment of the Effectiveness of Vitamin Supplement in Treating Eczema: A Systematic Review and Meta-Analysis

Ziyu Zhu,1,2 Ziyi Yang,1,2 Chunyi Wang,1,3 and Handeng Liu1

1Laboratory of Tissue and Cell Biology, Experimental Teaching and Management Center, Chongqing Medical University, Chongqing 400016, China
2The First Clinical College, Chongqing Medical University, Chongqing 400016, China
3College of Pediatrics, Chongqing Medical University, Chongqing 400016, China

Correspondence should be addressed to Handeng Liu; hdliu@cqmu.edu.cn

Received 2 April 2019; Accepted 29 July 2019; Published 31 October 2019

Academic Editor: Alfredo Vannacci

Copyright © 2019 Ziyu Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The morbidity of eczema has increased in the recent years, and the methods to prevent or ameliorate its effects are becoming more important. To this end, this research was conducted to determine the effectiveness of vitamin supplements in eczema therapy.

Method. Embase, PubMed, and Cochrane Central Register of Clinical Trials were searched. Only randomized controlled trials were included, and we included all quantified eligible data where the SCORing Atopic Dermatitis (SCORAD) Index or Eczema Area and Severity Index (EASI) scores were applied to assess the severity of eczema.

Results. Ten studies fulfilled the inclusion criteria, and eight of them were included for quantitative analysis (total: 456 patients). Compared to the controls, the SCORAD index or EASI decreased in the vitamin supplement group (mean difference $-5.96$, 95% CI: $-7.69$ to $-4.23$ for vitamin D3; mean difference $-5.72$, 95% CI: $-11.41$ to $-0.03$ for vitamin E; and mean difference $-3.19$, 95% CI: $-4.27$ to $-2.10$ for vitamin B12).

Conclusion. This study suggests that vitamin supplements could be important therapeutics to help manage eczema patients.

1. Introduction

Eczema, a common skin irritation, often presents as a chronic, inflammatory, and pruritic skin abnormality. It encompasses a group of conditions, among which atopic dermatitis (AD) is the most prevalent type. Recently, the occurrence or prevalence of atopic dermatitis has increased in Africa, eastern Asia, and Western Europe [1]. Though drugs can effectively manage the symptoms and improve the life quality of most patients, a radical cure has yet to be found.

Vitamins play significant roles in maintaining normal body function. For instance, vitamin D, especially vitamin D3, had been linked to dermatological disorders, including atopic dermatitis. The metabolite of D3, 1,25-dihydroxyvitamin D3 [2, 3], as well as vitamin E and vitamin C, have long been applied for skin care as antioxidants to maintain cellular redox balance [4]. Vitamin B12, also known as cobalamin, has a complex relationship with the skin and is thought to help lessen eczema symptoms by reducing nitric oxide levels [5–7]. Previous studies have suggested that vitamins, especially vitamin E, vitamin D, and vitamin B12, may be useful in the treatment of atopic eczema (AE); however, more evidence is needed before vitamin supplements can be recommended for atopic eczema [7]. For example, although the use of vitamin D3 was found to be inversely associated with the severity of AD, the results of other studies have been conflicting [8]. Therefore, the present study was performed to ascertain the efficacy of vitamin supplements for treating eczema. Other meta-analyses have demonstrated vitamin supplementation to be a viable treatment option for eczema, but all the studies were limited to a single type of vitamin. Consequently, the present study included all types of vitamins and only randomized controlled trials using the SCORing Atopic Dermatitis (SCORAD) Index or the Eczema Area and Severity Index (EASI) scores were included for qualitative and quantitative analyses to ensure the quality of our study.
The scoring atopic dermatitis index is an evaluation system based on simplicity and ease of routine use in outpatient clinics. It evaluates the extent, severity, and subjective symptoms (edema/papulation, erythema excoriation, oozing/crust, lichenification, and dryness) of AD [9]. EASI is an effective, easily understood tool for the evaluation of AD, focusing on crucial acute and chronic signs of inflammation (erythema, excoriation, induration/papulation, and lichenification) [10]. Quantitative analyses for vitamin D3, vitamin B12, and vitamin E were conducted in the present study.

2. Materials and Methods

This meta-analysis was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) rules. The protocol for this meta-analysis was registered on PROSPERO (CRD42018117330).

2.1. Search Strategy and Data Collection. Electronic databases, including PubMed (up to January 2019), Embase (up to January 2019), and Cochrane Central Register of Clinical Trials (up to January 2019), were searched using the keywords "eczema AND vitamin" to identify studies on patients diagnosed with eczema using clinical diagnoses or validated diagnostic criteria. The detailed search strategy can be accessed in Additional File 1.

All the search results were screened by two independent reviewers. Initially, the studies were identified by titles, and then the abstracts of the related papers were assessed to find articles for further full-text screening before final inclusion in the systematic review. A flow diagram of the selection process is shown in Figure 1.

All the search results were screened by two independent reviewers. Initially, the studies were identified by titles, and then the abstracts of the related papers were assessed to find articles for further full-text screening before final inclusion in the systematic review. A flow diagram of the selection process is shown in Figure 1.

2.2. Study Selection and Data Extraction. Studies met the following criteria for inclusion in our analyses: (1) participants: eczema patients with a clinical diagnosis; (2) interventions: information on vitamin supplements, dosage intervals, dosage, and route of administration. The types of vitamins were not restricted. The comparator was limited; only studies which examined placebo groups or no vitamin supplement groups were included; (3) outcome measures: the SCORAD index or EASI; and (4) types of studies: only articles on randomized controlled trials (RCT) written in English were included. Animal studies, case reports, and review articles were omitted.

All data were obtained in duplicate from the included articles and were recorded on a form designed independently by two of the authors in advance. No blending of authorship existed in the process. Data extracted from each article included authors, countries, publication year, study design, inclusion and exclusion criteria, interventions introduced, number randomized and analyzed, and outcomes measured by the SCORAD Index or EASI scores.

2.3. Quality of Assessment. Discrepancies between the two reviewers were resolved by discussion or by obtaining the opinion of a third evaluator, and a consensus was finally achieved. The assessment of bias was conducted using the Cochrane Collaboration Risk of Bias Tool for randomized controlled trials. The risks assessed included random sequence generation, allocation concealment, incomplete outcome data, blinding, selective reporting, and other biases. After individual rating and discussion, a consensus was reached (Figures 2 and 3). To rate the quality of the evidence, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was used, according to the five downgraded criteria: risk of bias, inconsistency, indirectness, imprecision, and publication bias (Figure 4). In addition, a sensitivity analysis was performed to test every single study’s influence on the stability of the entire quantitative analysis for vitamin D3 (Figure 5).

2.4. Statistical Analyses. Fixed effects models were used to calculate the weighted mean difference or standardized mean difference (MD) with 95% confidence intervals (CI) to assess the effectiveness of vitamin use to relieve or prevent eczema using Cochrane Collaboration’s software (RevMan 5.3). A sensitivity or specificity test was conducted using STATA 15.1. The correlation factor suggested by the Cochrane Collaboration Tool was set to 0.5 to calculate variance. Heterogeneity was checked using I² statistics, and meaningful heterogeneity was determined by 50% of the I² value.

3. Results

The initial search identified 1096 studies, and 98 were selected for full-text screening. Only 10 studies evaluated the SCORAD Index or EASI score in eczema patients and controls, fulfilling the inclusion criteria. They were included for qualitative analysis, and eight of them were included in the quantitative synthesis. All the included articles assessed the effectiveness of vitamin supplements in eczema patients using the SCORAD Index or EASI scores. The characteristics of the included articles are summarized in Table 1.

3.1. Comparison of the SCORAD Index or EASI Scores of the Vitamin Supplement Group and Placebo Group. Ten RCTs were included in the review. The sample sizes ranged from 5 to 57. The studies were published from 2008 to 2018. Five studies were conducted on atopic dermatitis, three studies were conducted on pediatric atopic dermatitis, and two studies were conducted on winter-related atopic dermatitis.

Compared to the control group, the SCORAD Index of the patients given different vitamins was significantly lower, especially in the study by Javanbakht et al. [12], where combined supplementation with both vitamin E and vitamin D3 was better than any other single vitamin used in that study (−23.1 for combined vitamins group vs. −12.9 for single vitamin E group).
3.2. Vitamin D3 Supplementation in Atopic Dermatitis Patients. In all, the data from 148 atopic dermatitis patients and 135 controls in the RCTs were included in the quantitative analysis. Amestejani et al. [11] only included patients aged 14 or older, Javanbakht et al. [12] included patients aged 13 to 45 years old, and Lara-Corrales et al. [14] included patients between the ages of 0 and 18 years. Armendariz et al. [13] included patients aged 2–54, and Camargo et al. [18] included patients with a mean age of 9 (SD = 5).

The results showed that the SCORAD Index or EASI scores decreased in patients given vitamin D3 (cholecalciferol) supplements (mean difference $-5.96$, 95% CI: $-7.69$ to $-4.23$). The $I^2$ statistic suggested that no meaningful heterogeneity was detected across the studies ($I^2 = 33\%$) (Figure 6).

3.3. Vitamin B12 Supplementation in Atopic Dermatitis Patients. Two randomized controlled trials testing the effectiveness of vitamin B12, both measured by the SCORAD index, were included in our analysis. The results showed that the SCORAD Index decreased after the topical application of vitamin B12-containing cream (mean difference $-3.19$, 95% CI: $-4.27$ to $-2.10$). No meaningful heterogeneity was detected ($I^2 = 0\%$) (Figure 7).
Other bias
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)

Figure 2: Risk of bias graph of all included studies.

| Study          | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
|---------------|-----------------------------|------------------------|----------------------------------------|-------------------------------|------------------------|---------------------|------------|
| Amestejani 2012 | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Camargo 2014   | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Gall 2014      | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Jaffary 2015   | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Januchowski 2009 | Low risk                | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Javanbakht 2011 | Unclear risk            | Unclear risk           | Unclear risk                           | Unclear risk                  | Unclear risk           | Unclear risk       | Unclear risk |
| Lara-corrales 2018 | High risk               | High risk              | High risk                              | High risk                     | High risk              | High risk          | High risk  |
| Nistico 2017   | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Sanchez Armendariz 2017 | Low risk            | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Sidbury 2008   | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |
| Others         | Low risk                  | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk           | Low risk   |

Figure 3: Risk of bias summary for each included study.

Vitamin D3
SCORAD or EASI
The mean vitamin D3 in the intervention groups was 5.96 lower (7.69 to 4.23 lower)

Vitamin B12
SCORAD
The mean vitamin B12 in the intervention groups was 3.19 lower (4.27 to 2.1 lower)

Vitamin E
SCORAD
The mean vitamin E in the intervention groups was 5.72 lower (11.41 to 0.03 lower)

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes (1 and 2). The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CIs: confidence interval;
GRADE working group grades of evidence:
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.

1The detection bias in Nistico 2017 was at high risk.
2The sample size included is relatively small.

Figure 4: Summary of findings.
Figure 5: Sensitivity analysis for included studies on vitamin D3 supplementation.

### Table 1: Characteristics of the included studies.

| First author year (Reference) | Country | Study design | Sample size (I vs. C) | Inclusion criteria | Exclusion criteria | Intervention | Control | Mean change (I vs. C) |
|-------------------------------|---------|--------------|----------------------|--------------------|-------------------|--------------|---------|---------------------|
| Amestejani 2012 [11] | Iran | RCT | 29 vs. 24 | Age 14 and older, with no concomitant pyretic, systemic disease or inflammatory processes | Pregnancy, concomitant systemic inflammatory disorder, and use of vitamins, minerals and fatty acids supplements, oral contraceptive pills, antiepileptic agents, steroid hormones, anticoagulant drugs | Placebo filled with starch identical in size and color | SCORAD | −9.5, −1.84 |
| Javanbakht 2011 [12] | Iran | RCT | GD3: 12, GE4: 11, GDE5: 11 vs. GP6: 11 | Patients with SCORAD from 10 to 70 | Patients taking vitamins, minerals and fatty acids supplements, oral contraceptive pills, antiepileptic agents, anticoagulant drugs, and pregnant or nursing mothers | GD3: 1600 IU vitamin D3 and vitamin E placebo daily; GE4: 600 IU vitamin E and vitamin D3 placebo daily; GDE5: 1600 IU vitamin D3 and 600 IU vitamin E placebo daily | Vitamin D3 placebo filled with starch, vitamin E placebo filled with mineral oil | SCORAD | −12.9, −9.4, −13.9 |
| Sanchez Armendariz 2018 [13] | Mexico | RCT | 29 vs. 29 | Patients diagnosed with moderate-severe AD | Patients with primary immunodeficiency, renal tubular acidosis, and pregnancy and those taking other supplements, as well as lack of follow-up at 12 weeks | 5000 IU vitamin D3 daily for 3 months | Cellulose | −21.2, −13.9 |
| First author year (Reference) | Country | Study design | Sample size (I vs. C) | Inclusion criteria | Exclusion criteria | Intervention | Control | Main outcome Mean change (I vs. C) |
|-------------------------------|---------|--------------|-----------------------|--------------------|-------------------|--------------|---------|----------------------------------|
| Lara-Corrales 2018 [14]       | Canada  | RCT          | 21 vs. 24             | Patients aged 0-18 with a clinical diagnosis of AD | Patients with known renal or liver disease or chronic dermatological conditions other than AD | 2000 IU vitamin D3 (2 drops of vitamin D3, 1000 IU/drop) daily for 3 months | Identical-appearing placebo drops | SCORAD $-15.4$, $-15.3$ |
| Januchowski 2009 [15]         | America | RCT          | 21 vs. 21             | Children aged 6-18 years with eczema and the ability to understand the consent process | Unwillingness of the parents to consent to the study protocol; pregnancy or lactation; eczema with superinfection present; known history of allergy to vitamin B12 or components of the base cream; topical treatment with corticosteroids in the 4 weeks prior to enrollment; or inability to speak and read English | 0.07% vitamin B12 twice a day for 4 weeks | The same moisturizing base without vitamin B12 | SCORAD $-4.52$, $-1.61$ |
| Jaffary 2015 [16]             | Iran    | RCT          | 33 vs. 32             | Patients aged 10-50 years with a clinical diagnosis of AD | Severe disease, requiring hospitalization, pregnant women, nursing mothers, coagulopathies, use of anticoagulant medications, systemic corticosteroids or immunosuppressants, as well as having a history of allergy to vitamin E, and living in long distances from Isfahan city; those patients who showed severe allergic symptoms to vitamin E and those who became pregnant during the therapy | 400 IU vitamin E daily 4 months oral | Placebo with no active ingredient and without smell | SCORAD $-11.12$, $-3.89$ |
| Sidbury 2008 [17]             | America | RCT          | 5 vs. 6               | Unclear            | Unclear           | 1000 IU vitamin D2 daily for 1 month 1000 IU vitamin D3 daily for 1 month | Identical looking placebo | EASI $-4.6$, $-2.2$ |
| Camargo 2014 [18]             | Mongolia| RCT          | 57 vs. 47             | Patients aged 2-17 years with winter-related AD | Patients with an active skin infection | 1000 IU vitamin D3 daily for 1 month | Colorless, odorless and tasteless placebo | EASI $-6.5$, $-3.3$ |
3.4. Vitamin E Supplementation in Atopic Dermatitis Patients.

Two randomized controlled trials testing vitamin E on patients with eczema, both measured by the SCORAD Index, were included in our analysis. The results suggested that the SCORAD Index improved after vitamin E supplementation (mean difference \(-5.72, 95\% \text{ CI: } -11.41 \text{ to } -0.03\)). No meaningful heterogeneity was detected (\(I^2 = 0\%\)) (Figure 8).

3.5. Adverse Effects. Javanbakht et al. [12] reported two exacerbated patients: one in the placebo group (11.7%) and one in the vitamin E group (27.7%). The study by Januchowski [15] reported that one patient withdrew earlier due to apparent side effects of both the placebo and study creams.

4. Discussion

In the present study, we included and comprehensively analyzed randomized controlled trials and generated potentially important conclusions. According to the results of the quantitative analyses in the RCTs (Amestejani et al. [11],
Javanbakht et al. [12], Lara-Corrales et al. [14], and Armendariz et al. [13]), the condition of atopic dermatitis patients, particularly those with moderate-to-severe disease, was improved after treatment with vitamin D3 (cholecalciferol) supplements (mean difference $-7.15$, 95% CI: $-9.21$ to $-5.08$). Additionally, Jaffary et al. [16] and Javanbakht et al. [12] administrated $400\text{ IU}$ and $600\text{ IU}$ of vitamin E, respectively, and showed favorable improvement in the SCORAD Index (SCORAD change: $11.12$ compared to $12.9$ for placebo group: $-3.89$, $p < 0.05$; SCORAD change: $-12.9$ compared to placebo group: $-9.4$, respectively). Of note, the studies by Januchowski et al. [15] and Nistico et al. [20] treated patients with a topical cream containing vitamin B12 (0.07% cyanocobalamin by weight in a moisturizing base and 0.07% vitamin B12 in a barrier cream embedded in a polysorbate carrier system designed to penetrate the skin with a lipid concentration of 24% and 1% urea, respectively). Their results suggested improvements as well (SCORAD change $=-4.52$ compared with placebo $=-1.61$ by Januchowski et al. [15] and SCORAD change $=-4.65$ compared with placebo $=-1.09$ by Nistico et al. [20]). In the study by Javanbakht et al. [12], the researchers designed a vitamin E and vitamin D3 combined group, as well as single-supplemented groups to assess the effect of the treatments on the clinical manifestation of atopic dermatitis (SCORAD change: $-23.1$ compared with placebo: $-9.4$).

Vitamin D is in a family of nutrients that share similarities in chemical structures. Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) are the most common members of this large family. General speaking, vitamin D3 is more effective in improving vitamin D status, though both are important in maintaining health [21, 22]. Hence, the study by Sidbury et al. [17] was not consolidated with the other studies using vitamin D3 supplements because vitamin D2 was evaluated in that trial. With the aim of assessing the durability of the response to treatment with vitamin supplements, only Jaffary et al. [16] analyzed relapse rates. Twenty-five percent of the patients in the treatment group (7/28) versus 22.2% in the placebo group (6/21) relapsed after treatment with vitamins.

Presently, through a set of systematic remedies ranging from emollients to corticosteroids, we are able to manage most of the symptoms of eczema [23]. Although the exact etiology of eczema is still unknown, a combination of genetic and environmental factors is involved. Dysfunction of the natural skin barrier has been considered one of the main pathophysio-logic theories. It occurs not as a driver but as a consequence of eczema, and filaggrin deficiency has been implicated in the pathogenesis of atopic dermatitis due to its significant role in homeostasis of the skin [24, 25]. The patient’s immune function and dysfunction are involved in the pathogenesis, too, which involves a sophisticated network of immune response proteins [26]. For instance, from deeply-sequenced RNA samples using long paired-end reads, a recent study reported that atopic dermatitis was an IL-13-dominated disease [27]. In another study, the researchers suggested that inflammasome-dependent IL-1β was involved in the pathogenesis based on a confirmed correlation between patients’ AD severity and IL-1Ra [28]. A systematic review assessed 48 publications and also suggested that IL-17, as well as IL-22, seemed to play roles in the pathogenesis of allergic skin maladies [29]. Further studies are needed to accurately identify the mechanism of eczema progression. Meanwhile, connections between vitamins and the disease are being increasingly discovered. A recent study reported that vitamin D3 might ameliorate atopic dermatitis by producing tolerogenic dendritic cells to the allergic phenotype in children [30]. Vitamin E may affect the immune function directly by altering the membrane function or by indirectly affecting a sophisticated signaling pathway by affecting inflammatory mediators [31]. Vitamin C was found to improve the overall epidermal barrier function by modulating ceramide metabolic-related enzymes, thereby increasing ceramide production [32]. Nevertheless, to fully elucidate the specific mechanisms involved, far more studies are needed.

Our results agree with other similar systematic reviews and meta-analyses [33–35], which determined the efficacy of vitamin D supplements to treat atopic dermatitis. However, this study only included randomized controlled trials measuring outcomes with the SCORAD Index or EASI scores, and the types of vitamins analyzed were not limited to a single one. Of note, in a study conducted by Galli et al. [19], 3-month consecutive supplementation with vitamin D3 (2000 IU daily) failed to show a statistical correlation between the serum levels of vitamin D and eczema severity [36]. In comparison with the other five studies, the mean baseline of the SCORAD index in that study was much lower (12.2 in Galli et al. [19], 24.8 in Amesteanjii et al. [11], 36 in Javanbakht et al. [12], 27.3 in Lara-Corrales et al. [14], and 41.5 in Armendariz et al. [13]). The severity of eczema in this study was evaluated according to the commonly used SCORAD classification (mild for $0–25$, moderate for $26–50$, and severe for $51–103$), which seems to be an update from the experts of the previously suggested severity strata for oSCORAD in 1997 [30, 31]. Therefore, we suspect that the lack of outcome correlations might be explained by the comparison of different interpretations of
the SCORAD Index and total baseline scores. After a detailed review of the five other studies analyzing the baseline scores and SCORAD cutoffs in each study, we found that Galli et al.’s study [19] was the only study whose enrolled experimental group could be considered as having mild eczema, while patients in the other five studies had moderate eczema. In the study by Camargo et al. [18], 89% of the 107 children had moderate disease. Moreover, in recent studies, researchers found that the serum vitamin D levels in patients with milder forms of atopic dermatitis were significantly higher, which might help clarify the disparate outcomes [37–40].

In conclusion, the present study summarized the latest evidence for treating atopic dermatitis patients by administering vitamin supplements. Due to the limited number of included studies, meta-analysis was conducted for several kinds of vitamins used in the selected studies. It confirmed the favorable efficacy of this daily treatment, especially in patients with moderate-to-severe AD. In addition, vitamin E and vitamin B12 were also found beneficial for AD patients. Our conclusions should be interpreted with some caveats. First, the total sample size was still relatively small. Second, potential confounding factors, such as the use of topical steroids or calcineurin inhibitors, were not adjusted. Despite these limitations, we still consider this study useful to verify the positive effects of vitamin supplements to relieve the severity of patients’ symptoms. Larger randomized controlled trials are required to determine the optimum ways to use vitamin supplements to treat atopic dermatitis, and thus, manage patients with different severities using the most effective supplement possible.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Ziyu Zhu designed and conceptualized this study, processed the raw data, performed the preliminary search, and drafted and wrote the initial manuscript. Ziyi Yang collected the data and performed the data analysis and was responsible for methodology. Ziyu Zhu and Ziyi Yang were responsible in software. Ziyu Zhu, Ziyi Yang, and Chunyi Wang were responsible for investigation and validation of the study. Ziyu Zhu and Ziyi Yang were responsible for formal analysis and data curation. Chunyi Wang and Ziyi Yang wrote, reviewed, and edited the manuscript. Handeng Liu supervised the work and was involved in funding acquisition.

Acknowledgments

This research was supported by the Project of Science and Technology of Chongqing Yuzhong District under grant No. cstc2017jjcAX0113, and the Project of Scientific Research and Innovative Experiment for College Students in the Chongqing Medical University (SRIEP201957).

Supplementary Materials

Table S1: detailed search strategy and results supporting this study (Embase, PubMed and the Cochrane Central Register of Clinical Trials). All the search history was retrieved from the database website. Table S2: the raw data extracted and processed for further quantitative analysis of vitamin supplement effectiveness. (Supplementary Materials)

References

[1] M. Kirk, I. A. G. Deckers, S. McLean et al., “Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies,” *PLoS One*, vol. 7, no. 7, Article ID e39803, 2012.
[2] E. Kechichian and K. Ezzedine, “Vitamin D and the skin: an update for dermatologists,” *American Journal of Clinical Dermatology*, vol. 19, no. 2, pp. 223–235, 2018.
[3] B. W. Hollis, “Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D,” *The Journal of Nutrition*, vol. 135, no. 2, pp. 317–322, 2005.
[4] F. A. S. Addor, “Antioxidants in dermatology,” *Anais Brasileiros de Dermatologia*, vol. 92, no. 3, pp. 356–362, 2017.
[5] J. Brescoll and S. Daveluy, “A review of vitamin B12 in dermatology,” *American Journal of Clinical Dermatology*, vol. 16, no. 1, pp. 27–33, 2015.
[6] B. L. Vieira, N. R. Lim, M. E. Lohman, and P. A. Lio, “Complementary and alternative medicine for atopic dermatitis: an evidence-based review,” *American Journal of Clinical Dermatology*, vol. 17, no. 6, pp. 557–581, 2016.
[7] A. Wollenberg, S. Barbarot, T. Bieber et al., “Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II,” *Journal of the European Academy of Dermatology and Venereology*, vol. 32, no. 6, pp. 850–878, 2018.
[8] O. Su, A. G. Bahalı, A. D. Demir, D. B. Ozkaya, S. Uzuner, and D. Dizman, “The relationship between severity of disease and vitamin D levels in children with atopic dermatitis,” *Advances in Dermatology and Allergology*, vol. 34, no. 3, pp. 224–227, 2017.
[9] J. F. Stalder, A. Taieb, D. J. Atherton et al., “Severity scoring of atopic dermatitis: the SCORAD index. consensus report of the european task force on atopic dermatitis,” *Dermatology*, vol. 186, no. 1, pp. 23–31, 1993.
[10] J. M. Hanifin, M. Thurston, M. Omoto et al., “The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis,” *Experimental Dermatology*, vol. 10, no. 1, pp. 11–18, 2001.
[11] M. Amestejani, B. S. Salehi, M. Vasigh et al., “Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study,” *Journal of Drugs in Dermatology*, vol. 11, no. 3, pp. 327–330, 2012.
[12] M. H. Javanbakht, S. A. Keshavarz, M. Djalali et al., “Randomized controlled trial using vitamins e and D supplementation in atopic dermatitis,” *Journal of Dermatological Treatment*, vol. 22, no. 3, pp. 144–150, 2011.
Evidence-Based Complementary and Alternative Medicine

K. Sanchez Armendariz, A. Garcia Gil, J. Contreras Ruiz, M. Karam Orante, and J. Dominguez Cherit, “Oral vitamin D3 5000IU as an adjuvant in the treatment of atopic dermatitis: a randomized controlled trial,” *Journal of Investigative Dermatology*, vol. 137, no. 5, p. 547, 2017.

I. Lara-Corrales, C. M. Huang, P. C. Parkin et al., “Vitamin D level and supplementation in pediatric atopic dermatitis: a randomized controlled trial,” *Journal of Cutaneous Medicine and Surgery*, vol. 23, no. 1, pp. 44–49, 2018.

R. Januchowski, “Evaluation of topical vitamin B12 for the treatment of childhood Eczema,” *The Journal of Alternative and Complementary Medicine*, vol. 15, no. 4, pp. 387–389, 2009.

F. Jaffary, G. Faghihi, A. Mokhtarian, and S. M. Hosseini, “Effects of oral vitamin E on treatment of atopic dermatitis: a randomized controlled trial,” *Journal of Research in Medical Sciences*, vol. 20, no. 11, pp. 1053–1057, 2015.

R. Sidbury, A. F. Sullivan, R. I. Thadhani, and C. A. Camargo Jr., “Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in children: a pilot study,” *British Journal of Dermatology*, vol. 159, no. 1, pp. 245–247, 2008.

C. A. Camargo, D. Gammia, R. Sidbury, K. Erdenedelger, N. Radnaakhand, and B. Khandsuren, “Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children,” *Journal of Allergy and Clinical Immunology*, vol. 134, no. 4, pp. 831–835.e1, 2014.

E. Galli, L. Rocchi, R. Carello, P. G. Giampietro, P. Panei, and P. Meglio, “Serum vitamin D levels and vitamin D supplementation do not correlate with the severity of chronic eczema in children,” *European Annals of Allergy and Clinical Immunology*, vol. 47, no. 2, pp. 41–47, 2015.

S. P. Nisticò, E. Del Duca, F. Tamburi et al., “Superiority of a vitamin B12-barrier cream compared with standard glycerol-petrolatum-based emollient cream in the treatment of atopic dermatitis: a randomized, left-to-right comparative trial,” *Dermatologic Therapy*, vol. 30, p. 5, article e12523, 2017.

D. D. Biké, “Vitamin D metabolism, mechanism of action, and clinical applications,” *Chemistry & Biology*, vol. 21, pp. 319–329, 2014.

B. W. Hollis, “Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their major metabolites,” *Journal of Steroid Biochemistry*, vol. 21, no. 1, pp. 81–86, 1984.

L. Solman, A. Lloyd-Lavery, D. J. C. Grindlay, N. K. Rogers, K. S. Thomas, and K. E. Harman, “What’s new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention,” *Clinical and Experimental Dermatology*, vol. 44, no. 4, pp. 363–369, 2019.

W. David Boothe, J. A. Tarbox, and M. B. Tarbox, “Atopic dermatitis: pathophysiology,” *Advances in Experimental Medicine and Biology*, vol. 1027, pp. 21–37, 2017.

B. Cabañillas and N. Novak, “Atopic dermatitis and filaggrin,” *Current Opinion in Immunology*, vol. 42, pp. 1–8, 2016.

K. C. Barnes, “An update on the genetics of atopic dermatitis: scratching the surface in 2009,” *Journal of Allergy and Clinical Immunology*, vol. 125, no. 1, pp. 16–29 e11, 2010.

L. C. Tsoi, E. Rodriguez, F. Degenhardt et al., “Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis,” *Journal of Investigative Dermatology*, vol. 139, no. 7, pp. 1480–1489, 2019.

E. Machura, M. Szczepańska, B. Mazur, K. Ziopa, and A. Kasperska-Zajac, “Interleukin 1-β, interleukin-1 receptor antagonist and vitamin D levels in children with atopic dermatitis,” *Central European Journal of Immunology*, vol. 43, no. 2, pp. 180–185, 2018.

M. A. Hofmann, F. Kiecker, and T. Zuberbier, “A systematic review of the role of interleukin-17 and the interleukin-20 family in inflammatory allergic skin diseases,” *Current Opinion in Allergy and Clinical Immunology*, vol. 16, no. 5, pp. 451–457, 2016.

F. Cristi, G. Perez-Mateuena, C. Vera-Kellet et al., “Vitamin D modulates the allergic phenotype of dendritic cells in children with atopic dermatitis,” *Experimental Dermatology*, vol. 28, no. 3, pp. 308–311, 2019.

E. D. Lewis, S. N. Meydani, and D. Wu, “Regulatory role of vitamin E in the immune system and inflammation,” *IUBMB Life*, vol. 71, no. 4, pp. 487–494, 2019.

K. P. Kim, K.-O. Shin, K. Park et al., “Vitamin C stimulates epidermal ceramide production by regulating its metabolic enzymes,” *Biomolecules & Therapeutics*, vol. 23, no. 6, pp. 525–530, 2015.

G. Kim and J.-H. Bae, “Vitamin D and atopic dermatitis: a systematic review and meta-analysis,” *Nutrients*, vol. 8, no. 12, p. 789, 2016.

C. M. Huang, I. Lara-Corrales, and P. Elena, “Effects of Vitamin D levels and supplementation on atopic dermatitis: a systematic review,” *Pediatric Dermatology*, vol. 35, no. 6, pp. 754–760, 2018.

B. Pope, A. P. Oranje, L. Labrèze, J.-F. Stalder, J. Ring, and A. Taieb, “Clinical validation and guidelines for the SCORAD index: consensus report of the European task force on atopic dermatitis,” *Dermatology*, vol. 195, no. 1, pp. 10–19, 1997.

R. Chopra, P. P. Vakharia, R. Sacotte et al., “Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis,” *British Journal of Dermatology*, vol. 177, no. 5, pp. 1316–1321, 2017.

D. G. Peroni, G. L. Piacentini, E. Cametti, I. Chinellato, and A. L. Boner, “Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children,” *British Journal of Dermatology*, vol. 164, no. 5, pp. 1078–1082, 2011.

S. Farajzadeh, I. Reghabatpour, M. Aflatoonian, S. Mohammadi, and R. Amiri, “Assessment of serum level of 25-hydroxyvitamin D in Iranian children with atopic dermatitis, in Kerman city, an area with high sun exposure,” *Journal of Pakistan Association of Dermatologists*, vol. 25, no. 2, pp. 96–100, 2015.

T. F. Leung, S. S. Wang, A. P.-S. Kong, H. N.-H. Pong, G. W.-K. Wong, and K. L. Hon, “Relationship between eczema and serum vitamin D concentration in Hong Kong children,” *European Annals of Allergy and Clinical Immunology*, vol. 68, pp. 36–37, 2013.